Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
Abstract Background Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-12-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-017-0640-5 |
id |
doaj-95acd0d523754cb5850d60d2e9aa72d7 |
---|---|
record_format |
Article |
spelling |
doaj-95acd0d523754cb5850d60d2e9aa72d72020-11-24T23:24:42ZengBMCCardiovascular Diabetology1475-28402017-12-0116111010.1186/s12933-017-0640-5Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in TaiwanChia-Yu Chang0Yung-Hsin Yeh1Yi-Hsin Chan2Jia-Rou Liu3Shang-Hung Chang4Hsin-Fu Lee5Lung-Sheng Wu6Kun-Chi Yen7Chi-Tai Kuo8Lai-Chu See9College of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityDepartment of Public Health, College of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityCollege of Medicine, Chang Gung UniversityDepartment of Public Health, College of Medicine, Chang Gung UniversityAbstract Background Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. Methods Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan’s National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled. Patients were further divided into two groups: (1) DPP4i users: those taking DPP4i and (2) non-DPP4i users: those prescribed other hypoglycemic agents (HAs) as second-line drug. Study end point was defined by diagnosis of AF, addition of any third-line HA, or the end of the study period (December 31, 2013), whichever came first. Results A total of 16,017 DPP4i users and 74,863 non-DPP4i users were eligible for the study. For the DPP4i group, most patients were prescribed sitagliptin (n = 12,180; 76%). Among the non-DPP4i group, most patients took sulfonylurea (n = 60,606; 81%) as their second-line medication. DPP4i users were associated with a lower risk of new-onset AF compared with non-DPP4i users after propensity-score weighting (hazard ratio 0.65; P < 0.0001). Subgroup analysis showed that DPP4i user were associated with a lower risk of new-onset AF compared with non-DPP4i users in most subgroups. Multivariate analysis indicated that use of DPP4i was associated with lower risk of new-onset AF and age > 65 years, presence of hypertension, and ischemic heart disease were independent risk factors for new-onset AF. Conclusions Among patients with diabetes prescribed with metformin, the patients with DPP4i as second HA were associated with a lower risk of AF compared with the patients with other drugs as second HAs in real-world practice.http://link.springer.com/article/10.1186/s12933-017-0640-5Dipeptidyl peptidase-4 inhibitorType 2 diabetes mellitusAtrial fibrillation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chia-Yu Chang Yung-Hsin Yeh Yi-Hsin Chan Jia-Rou Liu Shang-Hung Chang Hsin-Fu Lee Lung-Sheng Wu Kun-Chi Yen Chi-Tai Kuo Lai-Chu See |
spellingShingle |
Chia-Yu Chang Yung-Hsin Yeh Yi-Hsin Chan Jia-Rou Liu Shang-Hung Chang Hsin-Fu Lee Lung-Sheng Wu Kun-Chi Yen Chi-Tai Kuo Lai-Chu See Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan Cardiovascular Diabetology Dipeptidyl peptidase-4 inhibitor Type 2 diabetes mellitus Atrial fibrillation |
author_facet |
Chia-Yu Chang Yung-Hsin Yeh Yi-Hsin Chan Jia-Rou Liu Shang-Hung Chang Hsin-Fu Lee Lung-Sheng Wu Kun-Chi Yen Chi-Tai Kuo Lai-Chu See |
author_sort |
Chia-Yu Chang |
title |
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan |
title_short |
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan |
title_full |
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan |
title_fullStr |
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan |
title_full_unstemmed |
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan |
title_sort |
dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in taiwan |
publisher |
BMC |
series |
Cardiovascular Diabetology |
issn |
1475-2840 |
publishDate |
2017-12-01 |
description |
Abstract Background Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes. Methods Over a 3-year period, 480,000 patients with diabetes were analyzed utilizing Taiwan’s National Health Insurance Research Database and 90,880 patients taking metformin as first-line therapy were enrolled. Patients were further divided into two groups: (1) DPP4i users: those taking DPP4i and (2) non-DPP4i users: those prescribed other hypoglycemic agents (HAs) as second-line drug. Study end point was defined by diagnosis of AF, addition of any third-line HA, or the end of the study period (December 31, 2013), whichever came first. Results A total of 16,017 DPP4i users and 74,863 non-DPP4i users were eligible for the study. For the DPP4i group, most patients were prescribed sitagliptin (n = 12,180; 76%). Among the non-DPP4i group, most patients took sulfonylurea (n = 60,606; 81%) as their second-line medication. DPP4i users were associated with a lower risk of new-onset AF compared with non-DPP4i users after propensity-score weighting (hazard ratio 0.65; P < 0.0001). Subgroup analysis showed that DPP4i user were associated with a lower risk of new-onset AF compared with non-DPP4i users in most subgroups. Multivariate analysis indicated that use of DPP4i was associated with lower risk of new-onset AF and age > 65 years, presence of hypertension, and ischemic heart disease were independent risk factors for new-onset AF. Conclusions Among patients with diabetes prescribed with metformin, the patients with DPP4i as second HA were associated with a lower risk of AF compared with the patients with other drugs as second HAs in real-world practice. |
topic |
Dipeptidyl peptidase-4 inhibitor Type 2 diabetes mellitus Atrial fibrillation |
url |
http://link.springer.com/article/10.1186/s12933-017-0640-5 |
work_keys_str_mv |
AT chiayuchang dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT yunghsinyeh dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT yihsinchan dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT jiarouliu dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT shanghungchang dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT hsinfulee dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT lungshengwu dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT kunchiyen dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT chitaikuo dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan AT laichusee dipeptidylpeptidase4inhibitordecreasestheriskofatrialfibrillationinpatientswithtype2diabetesanationwidecohortstudyintaiwan |
_version_ |
1725559383382818816 |